Selective Targeting with Precision-Engineered Miniproteins and Beyond

Time: 9:00 am
day: Conference Day Two

Details:

• Discuss strategies for designing miniproteins within strict size and stability constraints
• Address key challenges in combining de novo design with natural scaffold–based approaches
• Integrate structure- and sequence-driven approaches to unlock improved therapeutic properties

NEW COMPANY!

Speakers:

Gabor Oroszlan As an In Silico Lead, I manage the development and operational oversight of VRG’s proprietary miniprotein platform, AI-MPRO. I oversee in silico processes and guide Read more